Celgene Corporation announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective...
ReCor Medical announced the 6 month "on-medication" results from its RADIANCE-HTN SOLO clinical trial with simultaneous publication in Circulation, and...
ReCor Medical, Inc.and its parent company, Otsuka Medical Devices Co., Ltd. announced that primary endpoint results from the RADIANCE II pivotal trial were published in the Journal of the American Medical Association (JAMA)
ReCor Medical announced that the RADIANCE-HTN SOLO study with the Paradise renal denervation system met its primary efficacy endpoint and...
Fresenius Kabi announced it has been granted an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.
Merck KGaA, announced a worldwide in-licensing agreement with Debiopharm, Lausanne, Switzerland, for the development and commercialization of xevinapant (Debio 1143).
Novo Nordisk announced Switzerland as the first country to launch Xultophy (IDegLira) for people with Type 2 Diabetes. Xultophy is...
There is only limited agreement with respect to location, directionality and functional implications of brain structural alterations observed in patients with schizophrenia.
Takeda announced the launch of Latuda (lurasidone), its atypical antipsychotic for the treatment of patients with schizophrenia. The launch of...
Tesaro reports anaphylaxis, anaphylactic shock and other hypersensitivity reactions with treatment by Varubi injectable emulsion.